Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 198 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Nicotinamide Placebo Clear all
Completed Phase 3 Interventional Results available

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT01004978
View directory record Official record
Conditions
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Interventions
Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Doxorubicin-Eluting Beads, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Mitomycin, Pharmacological Study, Placebo Administration, Sorafenib Tosylate
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
281
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 183 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Phase 1Phase 2 Interventional

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

NCT00302744
View directory record Official record
Conditions
Anxiety
Interventions
Psilocybin (drug), Niacin, MRI
Drug · Other · Diagnostic Test
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers

NCT05592951
View directory record Official record
Conditions
Safety, Tolerance
Interventions
Crystal Light (once serving), Liquid IV with amino acids (one serving), Liquid IV with amino acids (two servings), Liquid IV with amino acids (three servings)
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Phase 4 Interventional Results available

Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19

NCT04809974
View directory record Official record
Conditions
Covid19, Sequelae of; Infection, Cognitive Symptom
Interventions
Niagen
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 30, 2026, 3:41 PM EDT
Not yet recruiting Phase 1 Interventional

NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome

NCT07278492
View directory record Official record
Conditions
Down Syndrome (DS)
Interventions
MIB-626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment

NCT03482167
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Niagen®, Placebo
Drug · Other
Lead sponsor
University of Delaware
Other
Eligibility
60 Years to 90 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT00105443
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Nicotinamide Riboside on Metabolism and Vascular Function

NCT03501433
View directory record Official record
Conditions
Aging, Lipemia
Interventions
Nicotinamide riboside chloride (Niagen), Placebo
Dietary Supplement
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Sep 30, 2026, 3:41 PM EDT
Active, not recruiting Phase 2 Interventional

Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging

NCT04120766
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment
Interventions
Nicorandil, Placebo
Drug
Lead sponsor
Gregory Jicha, MD, PhD
Other
Eligibility
70 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 30, 2026, 3:41 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Trial of Supplemental Vitamin A and Nicotinamide

NCT05702398
View directory record Official record
Conditions
Skin Cancer, Kidney Transplant Recipients
Interventions
Vitamin A, Nicotinamide, Other: Placebo
Drug · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin

NCT01756495
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Losmapimod, Moxifloxacin, Losmapimod matched Placebo, Moxifloxacin Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

NCT00064350
View directory record Official record
Conditions
Lung Cancer
Interventions
Sorafenib, Placebo
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
141
States / cities
Stanford, California • Aurora, Colorado • Boulder, Colorado + 103 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Not applicable Interventional Results available

GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures

NCT03462680
View directory record Official record
Conditions
Parkinson's Disease
Interventions
niacin, placebo
Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Sep 30, 2026, 3:41 PM EDT
Recruiting Phase 2 Interventional

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

NCT05194397
View directory record Official record
Conditions
Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Myeloid Leukemia
Interventions
Nicotinamide Riboside, Placebo, Exercise Intervention
Dietary Supplement · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Duarte, California • Philadelphia, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Phase 3 Interventional Results available

Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease

NCT03743636
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Nicotinamide riboside, Resveratrol, Placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Phase 2 Interventional Results available

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

NCT01218126
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
losmapimod, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • Torrance, California • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Phase 1 Interventional

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

NCT00533585
View directory record Official record
Conditions
Lung Cancer
Interventions
BAY 43-9006, Paclitaxel, Carboplatin, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Phase 2 Interventional Results available

Nicotinamide as an Early Alzheimer's Disease Treatment

NCT03061474
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Nicotinamide, Placebo Comparator
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Irvine, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

NCT01338870
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, 25 mg PF-04991532, 75 mg PF-04991532, 150 mg PF-04991532, 300 mg PF-04991532, Sitagliptin 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Little Rock, Arkansas • Roseville, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Phase 2 Interventional Results available

Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects

NCT00865709
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Wichita, Kansas • Metairie, Louisiana • Brockton, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Sep 30, 2026, 3:41 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Combination Gerotherapeutic Interventions for Healthspan Improvement

NCT07475546
View directory record Official record
Conditions
Healthspan Improvement, Aging, Longevity
Interventions
Rapamycin, Naltrexone, Metformin, NAD+, GSH, Infinite Supplement, Placebo/control, B12, Intervention: Guided Meditation Program, Control: Podcast Listening Activity, Control: Standard Exercise Regimen, Intervention: Structured Exercise Program
Drug · Dietary Supplement · Behavioral
Lead sponsor
AgelessRx
Industry
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 30, 2026, 3:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Protection From Acute Kidney Injury (AKI) With Basis™ Treatment

NCT04342975
View directory record Official record
Conditions
AKI
Interventions
Nicotinamide Riboside + Pterostilbene, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 30, 2026, 3:41 PM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

NCT06200155
View directory record Official record
Conditions
Depression, Anxiety, Psilocybin-Assisted Psychotherapy, Advanced Cancer
Interventions
Psilocybin, Niacin
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Sep 30, 2026, 3:41 PM EDT
Not yet recruiting Phase 2 Interventional

Nicotinamide Riboside Supplementation in Chronic Kidney Disease

NCT07693543
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Nicotinamide Riboside (NR), Matched Placebo (Capsules)
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
30 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 30, 2026, 3:41 PM EDT